Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma

STATEMENT OF NEED

Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their knowledge of RCC pathophysiology and the benefits and risks of novel therapies. In this activity presented at the Society of Government Service Urologists James C. Kimbrough Urological Seminar, Eric Jonasch, MD, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, imparts expert perspectives and details the latest treatment options for advanced RCC.

TARGET AUDIENCE

Military, academic, and private practice urologists, nurse practitioners, and physician assistants involved in the treatment of patients with renal cell carcinoma.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Discuss the immunogenicity of RCC and the implications for the treatment of advanced disease
Assess criteria for risk stratification of patients with advanced RCC
Evaluate recent clinical trial findings on novel treatment strategies for advanced RCC with checkpoint inhibitors and VEGFR-directed therapies